Compare ADMA Biologics Inc (ADMA) vs Futu Holdings Ltd (FUTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Futu Holdings Ltd — how do they compare? ADMA Biologics Inc trades at $9.87 (market cap $2.22B), while Futu Holdings Ltd trades at $104.7 (market cap $14.74B). The key difference: Futu Holdings Ltd is far larger — about 6.6× ADMA Biologics Inc's market cap, and Futu Holdings Ltd pays a 2.47% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | FUTU | |
|---|---|---|
Market Cap | $2.22B | $14.74B |
Sector | Health | Financials |
52-Week High | $20.38 | $199.04 |
52-Week Low | $7.60 | $89.76 |
Enterprise Value | $2.29B | $14.59B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Futu Holdings Limited (FUTU) trades at $105.31, down 3.12% on the day. The stock shows strong fundamentals with a P/E of 11.63 and robust profitability, including a net income margin of 41.83% and ROE of 28.09%. Revenue grew to $22.85B in 2025, and cash flow from operations surged to $31.0B in 2024. Technical indicators are bullish, with moving averages supporting an uptrend and key support at $103. However, recent earnings misses and a securities class action lawsuit pose significant headwinds.
The outlook for FUTU is mixed; strong financial health and analyst consensus leaning buy (58.34%) suggest potential upside, but legal risks and earnings volatility require caution. Investors should weigh solid fundamentals against regulatory and litigation overhangs that could impact near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →
